Jpmorgan Chase & CO Graphite Bio, Inc. Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Dec 26, 2024	BUY	$2.24 - $2.66 $40,687 - $48,316	18,164 New	18,164 $47,000
Q4 2023 Feb 12, 2024	SELL	$2.24 - $2.66 $23,589 - $28,012	-10,531 Reduced 36.7%	18,164 $47,000
Q3 2023 Nov 14, 2023	BUY	$2.18 - $2.77 $10,555 - $13,412	4,842 Added 20.3%	28,695 $71,000
Q2 2023 Aug 11, 2023	BUY	$2.47 - $3.38 $55,293 - $75,664	22,386 Added 1525.97%	23,853 $62,000
Q1 2023 May 11, 2023	SELL	$1.85 - $3.21 $4,521 - $7,845	-2,444 Reduced 62.49%	1,467 $3,000
Q4 2022 Feb 13, 2023	SELL	$2.82 - $3.59 $6,652 - $8,468	-2,359 Reduced 37.62%	3,911 $13,000
Q3 2022 Nov 14, 2022	BUY	$2.82 - $4.24 $3,446 - $5,181	1,222 Added 24.21%	6,270 $20,000
Q2 2022 Aug 11, 2022	SELL	$2.14 - $5.23 $33,114 - $80,929	-15,474 Reduced 75.4%	5,048 $14,000
Q1 2022 May 11, 2022	BUY	$5.1 - $13.06 $46,807 - $119,864	9,178 Added 80.91%	20,522 $105,000
Q4 2021 Feb 10, 2022	BUY	$8.41 - $16.71 $43,059 - $85,555	5,120 Added 82.26%	11,344 $141,000
Q3 2021 Nov 12, 2021	BUY	$15.81 - $28.39 $98,401 - $176,699	6,224 New	6,224 $102,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.